IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) shares traded down 8.9% on Wednesday . The stock traded as low as $0.51 and last traded at $0.61. 638,964 shares were traded during mid-day trading, an increase of 55% from the average session volume of 412,690 shares. The stock had previously closed at $0.56.
Several research analysts have recently weighed in on the company. Maxim Group set a $2.00 price target on IntelliPharmaCeutics Intl and gave the stock a “buy” rating in a research note on Friday, February 9th. Zacks Investment Research upgraded IntelliPharmaCeutics Intl from a “sell” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, HC Wainwright set a $3.00 price target on IntelliPharmaCeutics Intl and gave the stock a “buy” rating in a research note on Monday, March 5th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $2.53.
IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) last issued its quarterly earnings data on Friday, February 16th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.01). IntelliPharmaCeutics Intl had a negative return on equity of 2,811.75% and a negative net margin of 160.89%. The firm had revenue of $1.08 million during the quarter, compared to the consensus estimate of $1.32 million. equities research analysts forecast that IntelliPharmaCeutics Intl Inc will post -0.18 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in IntelliPharmaCeutics Intl stock. Sabby Management LLC acquired a new position in IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,083,637 shares of the company’s stock, valued at approximately $867,000. Sabby Management LLC owned 3.49% of IntelliPharmaCeutics Intl at the end of the most recent reporting period. Institutional investors and hedge funds own 11.31% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “IntelliPharmaCeutics Intl (IPCI) Trading Down 8.9%” was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/03/14/intellipharmaceutics-intl-ipci-trading-down-8-9.html.
IntelliPharmaCeutics Intl Company Profile
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.